HLA-A and acute myeloid leukemia: Neopeptides derived from FLT3-ITD of several AML cell lines or patients have been predicted with different affinity to HLA-A (A1, A2, A11, and A24) or HLA-B27, some of which showed intermediate or high affinity to HLA-A2 in a T2 cell-based assay [67].